Abstract
Brusatol is a natural product found in the plant Brucea javanica that is used to treat diseases such as amoebiasis and malaria. It also has significant anti-tumor effects. However, its role in lung cancer and the mechanism underlying its pharmacological effects remain unclear. In this study, we identified the core target of brusatol for lung adenocarcinoma (LUAD) therapy using network pharmacology and elucidated its therapeutic mechanism by conducting cell experiments. The therapeutic targets of brusatol were obtained from the PharmMapper database, the LUAD-related genes were obtained from the TCGA database, and the intersection targets of the two were taken as potential targets for treating LUAD with brusatol. Based on the results of the intersection, core target and signaling pathways were identified by protein-protein interaction (PPI), molecular docking, gene ontology (GO) function, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Finally, cell experiments were performed to determine the antineoplastic effect of brusatol on LUAD. We identified 328 potential targets of brusatol for treating LUAD, and the PPI network analysis identified ALB, SRC, HSP90AA1, HRAS, CASP3, MAPK1, and ESR1 as key genes. Through molecular docking, MAPK1 was identified as the core target of brusatol in LUAD. GO analysis revealed that brusatol may exert anti-tumor effects through endopeptidase activity, protein tyrosine kinase activity, and amide binding. KEGG enrichment analysis suggested that brusatol may treat LUAD by regulating the RAS signaling pathway. Brusatol inhibited the proliferation and invasion of LUAD cells and caused apoptosis and G2/M phase arrest in these cells. Further analysis confirmed that brusatol plays a role in treating LUAD by targeting MAPK1 and regulating the Ras signaling pathway. To summarize, through a combination of network pharmacological analysis and cell experimental validation, we revealed the mechanism underlying the therapeutic effects of brusatol on LUAD. This study also provided a theoretical basis for using brusatol as a candidate drug for the targeted therapy of LUAD.
Data availability
The original contributions presented in the study are included in the article/ Supplementary Material . Further inquiries can be directed to the corresponding author.
References
Wang, N. et al. A network pharmacology approach to determine the active components and potential targets of Curculigo Orchioides in the treatment of osteoporosis. Med. Sci. Monit. 23, 5113–5122. https://doi.org/10.12659/MSM.904264 (2017).
AACR Centennial Series. The biology of cancer metastasis: Historical perspective | Cancer Research | American Association for Cancer Research n.d. accessed December 8, (2025). https://aacrjournals.org/cancerres/article/70/14/5649/559515/AACR-Centennial-Series-The-Biology-of-Cancer
Elgebaly, S. A. et al. Effects of brusatol, bruceoside A, and bruceantin on P-388 lymphocytic leukemia cell respiration. J. Pharm. Sci. 68, 887–890. https://doi.org/10.1002/jps.2600680727 (1979).
Wong, R. S. Apoptosis in cancer: From pathogenesis to treatment. J. Exp. Clin. Cancer Res. 30, 87. https://doi.org/10.1186/1756-9966-30-87 (2011).
Tang, X. et al. Blockade of glutathione metabolism in IDH1-mutated glioma. Mol. Cancer Ther. 19, 221–230. https://doi.org/10.1158/1535-7163.MCT-19-0103 (2020).
Ren, D. et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. U S A. 108, 1433–1438. https://doi.org/10.1073/pnas.1014275108 (2011).
Xiang, Y. et al. Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JNK/p38 MAPK/NF-κb/Stat3/Bcl-2 signaling pathway. Biochem. Biophys. Res. Commun. 487, 820–826. https://doi.org/10.1016/j.bbrc.2017.04.133 (2017).
Zhou, J. et al. Brusatol inhibits laryngeal. cancer cell proliferation and metastasis via abrogating JAK2/STAT3 signaling mediated epithelial-mesenchymal transition. Life Sci. 284, 119907. https://doi.org/10.1016/j.lfs.2021.119907 (2021).
Dai, Z. et al. Brusatol inhibits proliferation and invasion of glioblastoma by down-regulating the expression of ECM1. Front. Pharmacol. 12, 775680. https://doi.org/10.3389/fphar.2021.775680 (2021).
Olayanju, A. et al. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2. Free Radic Biol. Med. 78, 202–212. https://doi.org/10.1016/j.freeradbiomed.2014.11.003 (2015).
Chen, H. et al. Brusatol reverses lipopolysaccharide-induced epithelial-mesenchymal transformation and induces apoptosis through PI3K/Akt/NF-кB pathway in human gastric cancer SGC-7901 cells. Anti-Cancer Drugs. 32, 394. https://doi.org/10.1097/CAD.0000000000001022 (2021).
Lee, J. H. et al. Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma. J. Adv. Res. 26, 83–94. https://doi.org/10.1016/j.jare.2020.07.004 (2020).
Chen, Z. et al. Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway. Phytomedicine 104, 154323. https://doi.org/10.1016/j.phymed.2022.154323 (2022).
Oh, E-T., Kim, C. W., Kim, H. G., Lee, J-S. & Park, H. J. Brusatol-mediated inhibition of c-Myc increases HIF-1α degradation and causes cell death in colorectal cancer under hypoxia. Theranostics 7, 3415–3431. https://doi.org/10.7150/thno.20861 (2017).
Cai, S. J., Liu, Y., Han, S. & Yang, C. Brusatol, an NRF2 inhibitor for future cancer therapeutic. Cell. Biosci. 9, 45. https://doi.org/10.1186/s13578-019-0309-8 (2019).
Feng, R-M., Zong, Y-N., Cao, S-M. & Xu, R-H. Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics? Cancer Commun. (Lond). 39, 22. https://doi.org/10.1186/s40880-019-0368-6 (2019).
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47–e47. https://doi.org/10.1093/nar/gkv007 (2015).
Dai, C. et al. Hsa_circ_0007312 Promotes third-generation epidermal growth factor receptor-tyrosine kinase inhibitor resistance through pyroptosis and apoptosis via the MiR-764/MAPK1 axis in lung adenocarcinoma cells. J. Cancer. 13, 2798–2809. https://doi.org/10.7150/jca.72066 (2022).
Yan, Z. et al. Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis. J. Exp. Clin. Cancer Res. 38, 221. https://doi.org/10.1186/s13046-019-1226-8 (2019).
Integrating signals from RTKs to ERK/MAPK |. Oncogene n.d. Accessed 08 Dec (2025). https://www.nature.com/articles/1210394
Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res. 53, D672–D677. https://doi.org/10.1093/nar/gkae909 (2024).
Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947–1951. https://doi.org/10.1002/pro.3715 (2019).
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. https://doi.org/10.1093/nar/28.1.27 (2000).
Luo, M. & Liang, C. LncRNA LINC00483 promotes gastric cancer development through regulating MAPK1 expression by sponging miR-490-3p. Biol. Res. 53, 14. https://doi.org/10.1186/s40659-020-00283-6 (2020).
Imran, M. et al. Luteolin flavonoid, as an anticancer agent: A review. Biomed. Pharmacother. 112, 108612. https://doi.org/10.1016/j.biopha.2019.108612 (2019).
Network pharmacology | Nature Biotechnology. n.d. Accessed 08 Dec (2025). https://www.nature.com/articles/nbt1007-1110
Yuan, C. et al. Network pharmacology and molecular docking reveal the mechanism of Scopoletin against non-small cell lung cancer. Life Sci. 270, 119105. https://doi.org/10.1016/j.lfs.2021.119105 (2021).
Network pharmacology based virtual screening of active constituents of Prunella vulgaris L. and the molecular mechanism against breast cancer | Scientific Reports n.d. https://www.nature.com/articles/s41598-020-72797-8 (2025). Accessed 08 December 2025.
He, S., Wang, T., Shi, C., Wang, Z. & Fu, X. Network pharmacology-based approach to understand the effect and mechanism of Danshen against anemia. J. Ethnopharmacol. 282, 114615. https://doi.org/10.1016/j.jep.2021.114615 (2022).
Network pharmacology. the next paradigm in drug discovery | Nature Chemical Biology n.d. Accessed 08 Dec (2025). https://www.nature.com/articles/nchembio.118
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584–594. https://doi.org/10.4065/83.5.584 (2008).
Jensen, M. et al. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Invest. New. Drugs. 26, 139–149. https://doi.org/10.1007/s10637-007-9106-z (2008).
McCubrey, J. A. et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773, 1263–1284. https://doi.org/10.1016/j.bbamcr.2006.10.001. (2007).
Wang, Y. et al. Selenium-binding protein 1 transcriptionally activates p21 expression via p53-independent mechanism and its frequent reduction associates with poor prognosis in bladder cancer. J. Transl Med. 18, 17. https://doi.org/10.1186/s12967-020-02211-4 (2020).
Targeting metastasis | Nature Reviews Cancer n. d. Accessed 08 Dec (2025). https://www.nature.com/articles/nrc.2016.25
Liu, Y. et al. Targeting tumor suppressor genes for cancer therapy. Bioessays 37, 1277–1286. https://doi.org/10.1002/bies.201500093 (2015).
Baritaki, S. et al. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: Role in sensitization to TRAIL apoptosis. Int. J. Oncol. 38, 1683–1694. https://doi.org/10.3892/ijo.2011.984 (2011).
The biology. and management of non-small cell lung cancer | Nature n.d. Accessed 08 Dec (2025). https://www.nature.com/articles/nature25183
Schafer, K. A. The cell cycle: A review. Vet. Pathol. 35, 461–478. https://doi.org/10.1177/030098589803500601 (1998).
Toward personalized treatment. approaches for non-small-cell lung cancer | Nature Medicine n.d. Accessed 08 Dec (2025). https://www.nature.com/articles/s41591-021-01450-2
Shao, L. I. et al., Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin. J. Nat. Med. 11, 110–120. https://doi.org/10.1016/S1875-5364(13)60037-0 (2013).
Shields, J. M., Pruitt, K., McFall, A., Shaub, A. & Der, C. J. Understanding Ras: ‘It ain’t over ’til it’s over’. Trends Cell Biol. 10, 147–154. https://doi.org/10.1016/S0962-8924(00)01740-2 (2000).
Wang, M. et al. UVA irradiation enhances brusatol-mediated inhibition of melanoma growth by downregulation of the Nrf2-mediated antioxidant response. Oxid. Med. Cell. Longev. 2018, 9742154. https://doi.org/10.1155/2018/9742154 (2018).
Author information
Authors and Affiliations
Contributions
Chunjiao Yang and Xin Jin contributed to conception and designed of the study. Shixiong Yang was responsible for manuscript revision. Dianzhu Pan performed the statistical analysis. Bo Jin wrote sections of the manuscript. Ye Zhang participated in the revision of the article.All authors contributed to the article and approved the submitted version.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethical approval
TCGA and HPA belong to public databases. The patients involved in the database have obtained ethical approval. Users can download relevant data for free for research and publish relevant articles. Our study is based on open source data, so there are no ethical issues and other conflicts of interest.The authors declare that the research was conducted in the absence of any com-mercial or financial relationships.The authors have stated explicitly that there are no conflict of interest in connection with this article.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Jin, X., Yang, S., Pan, D. et al. Combining network pharmacology and experimental validation to study the action and mechanism of brusatol against lung adenocarcinoma. Sci Rep (2026). https://doi.org/10.1038/s41598-026-45960-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-45960-w
